

NeuroMetrix Chief Commercial Officer Frank McGillin to Present Quell Wearable Pain Relief Technology at 16th Annual Diabetes Technology Meeting

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Senior Vice President and Chief Commercial Officer Frank McGillin will present on Quell® Wearable Pain Relief Technology™ during the 16th Annual Diabetes Technology Meeting, November 10-12, in Bethesda, Maryland.

About half of people with diabetes have chronic pain. In addition to the direct burden of pain symptoms, many of these individuals also report that their pain impacts sleep quality, activity level, and mood, all of which reduce quality of life and can exacerbate diabetes. Moreover, clinical studies have shown that chronic pain can limit diabetes self-care behaviors, which are essential for minimizing diabetes-related complications.

"We are excited to demonstrate Quell pain relief technology to the researchers who are leading the effort to discover innovative ways to address the challenges faced by people with diabetes," said McGillin. "Since one of the focus areas of this year's meeting is big data, we are particularly pleased to share early insights from the over 2,000,000 hours of user data captured in the Quell Health Cloud."

About the Diabetes Technology Society Annual Meeting

The Annual Meeting is an opportunity for leading scientists in the field of diabetes research to learn about the latest technological advances for people with diabetes. Last year's meeting in Bethesda, Maryland brought together over 450 clinicians and scientists from 24 countries to focus on applying science and technology to fight diabetes. Visit www.diabetestechology.org for more information.

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161110005824/en/>

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media